BALAXIPharmaceuticals
Balaxi Pharmaceuticals Ltd — Balance Sheet
₹15.67
-9.20%
Balaxi Pharmaceuticals Ltd Balance Sheet (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Net Debt | 12.22 Cr | — | — | — | 1.99 Cr |
| Total Debt | 53.43 Cr | 19.40 Cr | 13.31 Cr | 3.64 Cr | — |
| Tangible Book Value | 204.99 Cr | 174.49 Cr | 156.75 Cr | 89.04 Cr | — |
| Invested Capital | 283.36 Cr | 219.02 Cr | 194.50 Cr | 116.80 Cr | — |
| Working Capital | 188.23 Cr | 155.97 Cr | 140.38 Cr | 77.74 Cr | — |
| Net Tangible Assets | 204.99 Cr | 174.49 Cr | 156.75 Cr | 89.04 Cr | — |
| Capital Lease Obligations | 1.80 Cr | 1.74 Cr | 1.69 Cr | 0.00 | — |
| Common Stock Equity | 231.74 Cr | 201.36 Cr | 182.88 Cr | 113.16 Cr | — |
| Total Capitalization | 252.98 Cr | 201.36 Cr | 183.75 Cr | 113.16 Cr | — |
| Total Equity Gross Minority Interest | 231.74 Cr | 201.36 Cr | 182.88 Cr | 113.16 Cr | — |
| Stockholders Equity | 231.74 Cr | 201.36 Cr | 182.88 Cr | 113.16 Cr | — |
| Other Equity Interest | 220.69 Cr | 3.77 Cr | 10.30 Cr | 103.16 Cr | — |
| Capital Stock | 11.04 Cr | 10.90 Cr | 10.18 Cr | 10.00 Cr | — |
| Common Stock | 11.04 Cr | 10.90 Cr | 10.18 Cr | 10.00 Cr | — |
| Total Liabilities Net Minority Interest | 78.61 Cr | 56.98 Cr | 56.79 Cr | 63.31 Cr | — |
| Total Non Current Liabilities Net Minority Interest | 24.07 Cr | 2.78 Cr | 3.66 Cr | 0.04 Cr | — |
| Non Current Deferred Taxes Liabilities | 0.90 Cr | 1.00 Cr | 1.10 Cr | 0.04 Cr | — |
| Long Term Debt And Capital Lease Obligation | 23.05 Cr | 1.74 Cr | 2.56 Cr | 0.00 | — |
| Long Term Capital Lease Obligation | 1.80 Cr | 1.74 Cr | 1.69 Cr | 0.00 | — |
| Long Term Debt | 21.24 Cr | 0.00 | 0.87 Cr | 0.00 | — |
| Long Term Provisions | 0.13 Cr | 0.04 Cr | — | — | — |
| Current Liabilities | 54.53 Cr | 54.20 Cr | 53.13 Cr | 63.27 Cr | — |
| Other Current Liabilities | 4.61 Cr | 0.93 Cr | 0.84 Cr | 0.09 Cr | — |
| Current Debt And Capital Lease Obligation | 30.38 Cr | 17.66 Cr | 10.75 Cr | 3.64 Cr | — |
| Current Debt | 30.38 Cr | 17.66 Cr | 10.75 Cr | 3.64 Cr | — |
| Payables | 19.55 Cr | 32.73 Cr | 36.48 Cr | 52.29 Cr | — |
| Total Tax Payable | 3.37 Cr | — | 5.06 Cr | — | — |
| Accounts Payable | 16.18 Cr | 29.04 Cr | 34.52 Cr | 49.11 Cr | — |
| Total Assets | 310.34 Cr | 258.34 Cr | 239.67 Cr | 176.47 Cr | — |
| Total Non Current Assets | 67.58 Cr | 48.17 Cr | 46.16 Cr | 35.47 Cr | — |
| Other Non Current Assets | 4.52 Cr | 4.98 Cr | 1.92 Cr | 1.67 Cr | — |
| Investmentin Financial Assets | 0.00 | 0.00 | 0.00 | 4.47 Cr | — |
| Goodwill And Other Intangible Assets | 26.75 Cr | 26.88 Cr | 26.13 Cr | 24.13 Cr | — |
| Goodwill | 26.75 Cr | 26.10 Cr | 25.22 Cr | 23.30 Cr | — |
| Net PPE | 36.31 Cr | 16.31 Cr | 18.11 Cr | 5.20 Cr | — |
| Gross PPE | 36.31 Cr | 16.31 Cr | 18.11 Cr | 5.20 Cr | — |
| Construction In Progress | 22.07 Cr | 2.31 Cr | 2.83 Cr | 0.57 Cr | — |
| Other Properties | 14.24 Cr | 5.73 Cr | 5.91 Cr | 5.46 Cr | — |
| Current Assets | 242.77 Cr | 210.17 Cr | 193.51 Cr | 141.00 Cr | — |
| Other Current Assets | 10.98 Cr | 8.11 Cr | 5.20 Cr | 0.03 Cr | — |
| Inventory | 78.48 Cr | 82.17 Cr | 105.02 Cr | 98.70 Cr | — |
| Other Receivables | 3.11 Cr | 1.90 Cr | 1.65 Cr | 0.75 Cr | — |
| Accounts Receivable | 110.80 Cr | 55.71 Cr | 52.28 Cr | 27.56 Cr | — |
| Cash Cash Equivalents And Short Term Investments | 39.40 Cr | 62.29 Cr | 28.22 Cr | 7.19 Cr | — |
| Cash And Cash Equivalents | 39.40 Cr | 62.29 Cr | 28.22 Cr | 7.19 Cr | — |
| Other Payable | — | 3.69 Cr | 1.96 Cr | 3.17 Cr | 2.82 Cr |
| Ordinary Shares Number | — | 5.45 Cr | 5.09 Cr | 5.00 Cr | 5.00 Cr |
| Share Issued | — | 5.45 Cr | 5.09 Cr | 5.00 Cr | 5.00 Cr |
| Fixed Assets Revaluation Reserve | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | — | 135.80 Cr | 143.11 Cr | 91.86 Cr | 43.68 Cr |
| Additional Paid In Capital | — | 50.84 Cr | 19.25 Cr | 11.25 Cr | 11.25 Cr |
| Other Non Current Liabilities | — | 1000.00 | -1000.00 | 1000.00 | -4000.00 |
| Current Deferred Taxes Liabilities | — | 2.88 Cr | 5.06 Cr | 7.25 Cr | 6.01 Cr |
| Current Provisions | — | 2.88 Cr | — | 7.25 Cr | — |
| Dividends Payable | — | 47000.00 | 47000.00 | 31000.00 | 0.01 Cr |
| Non Current Prepaid Assets | — | 4.88 Cr | 1.88 Cr | 1.58 Cr | 0.02 Cr |
| Long Term Equity Investment | — | 0.00 | 0.00 | 0.00 | 3.42 Cr |
| Investmentsin Subsidiariesat Cost | — | 0.00 | 0.00 | 0.00 | 3.42 Cr |
| Other Intangible Assets | — | 0.78 Cr | 0.91 Cr | 0.82 Cr | — |
| Machinery Furniture Equipment | — | 8.27 Cr | 9.33 Cr | 4.57 Cr | 1.17 Cr |
| Buildings And Improvements | — | 52000.00 | 0.03 Cr | 0.06 Cr | 0.00 |
| Properties | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Prepaid Assets | — | 6.81 Cr | 5.27 Cr | 5.67 Cr | 1.02 Cr |
| Finished Goods | — | 82.17 Cr | 105.02 Cr | 98.70 Cr | 13.62 Cr |
| Taxes Receivable | — | 1.29 Cr | 1.07 Cr | 1.10 Cr | 1.23 Cr |
| Allowance For Doubtful Accounts Receivable | — | 0.00 | 0.00 | 0.00 | — |
| Gross Accounts Receivable | — | 55.71 Cr | 52.28 Cr | 27.56 Cr | — |
| Cash Financial | — | 62.29 Cr | 28.22 Cr | 7.19 Cr | 1.67 Cr |
| Available For Sale Securities | — | — | — | 4.47 Cr | — |
| Cash Equivalents | — | — | — | 31000.00 | 0.01 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Balaxi Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.